Very welcome to Theragnostic Talks by SAM Nordic, the one and only podcast about theragnostic. What is even theragnostic? And what does the future for it look like? In this podcast we will find out interesting science and get answers to curious questions by talking with true experts - clinicians, scientists and people from the industry. And to guide you through these episodes – Annette Andrén and Gustav Widar. Annette is driven by the transformation of science into value for patients. Her background as a chemical engineer - with focus on biochemistry - has led her to different positions such as country manager and market access director in the Nordics. She has been working both within a large variety of different therapy areas and with breakthrough treatments for inflammation and autoimmune diseases. What she likes the most is when she is able to help out in the identification of scientific opportunities for collaborations between Health care, Research and the Industry. She is currently senior medical science liaison at SAM Nordic. Gustav has a background as a licensed medical physicist and has worked many years in the field of nuclear medicine – covering imaging, therapy and the production of radiopharmaceuticals. He is driven by making medical innovations a clinical reality – where it really benefits the patient care. A couple of years ago he changed from healthcare to industry, now medical science liaison at SAM Nordic.
We need to increase knowledge and awareness of theragnostics and now is the time. That's the view of Lucy Morgan, associate director of research and policy at the Health Policy Partnership. But how do we do that? Listen to her talk about it and the Radioligand Therapy Readiness Hub. “People don't have to reinvent the wheel, not start from scratch. They can get great ideas and take advantage of hard work that has already been done”. New episode of Theragnostic Talks out now! Guest: Lucy Morgan By: Lisa Gruschy and Gustav Widar Contact us: podcast@samnordic.se For more info, visit www.samnordic.se
The world is on its way of taking a giant leap forward in the field of theragnostics. But are we ready for it? In this episode of Theragnostic Talks, we discuss readiness and the best way to raise awareness of theragnostics. How do we develop the field? And how do we expand the nuclear medicine practice to meet this challenge? Guests: Adj. Prof. Cristina Nanni, Prof. Andrei Iagaru, Prof. Louise Emmett, and Jeevan Virk, Head of RLT at Novartis. By: Gustav Widar, Medical Affairs Manager at SAM Nordic Contact us: podcast@samnordic.se For more information, visit: www.samnordic.se
What is it with FAPI and how does it work? In this episode of Theragnostic Talks, we take a closer look at the tracer that everyone's talking about. The new theragnostic tracer targets the tumour environment and can be used for both the diagnosis and treatment of a wide range of different types of cancers. Explaining this are Dr. Wolfgang Fendler, Prof. Thomas Hope, Kim M. Pabst, and Silvi Telo. Guests: Dr. Wolfgang Fendler, Prof. Thomas Hope, Kim M. Pabst, and Silvi Telo. By: Gustav Widar, Medical Affairs Manager Contact us: podcast@samnordic.se For more information, visit: www.samnordic.se
How do we move forward with prostate imaging? In today's episode of Theragnostic Talks, live from the EANM'22 Congress in Barcelona, we focus on PSMA-PET. How has PSMA-PET developed? Where are we regarding the diagnosis of prostate cancer? And how can we use PSMA-PET as a diagnostic tool for other forms of malignant tumours? Our thanks to Prof. Helle Damgaard Zacho, Dr. Daniela Oprea-Lager, and Simona Malaspina for sharing your expertise with us. Guests: Prof. Helle Damgaard Zacho, Dr. Daniela Oprea-Lager and Simona Malaspina. By: Gustav Widar, Medical Affairs Manager at SAM Nordic Contact us: podcast@samnordic.se For more information: www.samnordic.se
What is EANM? What have been the most burning questions through the years and in what ways do we want to move forward in this area? Theragnostic Talks will be live in Barcelona to talk with the leading experts in theragnostics. We start by taking a closer look at the journey that nuclear medicine has taken lately, and we will be doing this in the company of Prof. Jolanta Kunikowska, President of EANM, and Prof. Stefano Fanti, EANM Congress Chair. Guests: Prof. Jolanta Kunikowska and Prof. Stefano Fanti By: Gustav Widar, Medical Affairs Manager Contact us: podcast@samnordic.se For more information: www.samnordic.se
LuTectomy – LuPSMA in the very early stage of prostate cancer – what were the initial results? What difference does it make, choosing the right PSMA tracer? And how should PSMA-PET be used, according to the radiation oncologist? Listen to our eminent guests Declan Murphy, Stefano Fanti, Louise Emmett, Gert de Meerleer and Ken Herrmann talking about the future of theragnostics in urology, from the EAU 22 Congress in Amsterdam. Guests: Ken Herrmann, Gert de Meerleer, Louise Emmett, Stefano Fanti and Declan Murphy. By: Lisa Gruschy and Gustav Widar Contact us: podcast@samnordic.se For more info, visit www.samnordic.se
Using biomarkers from a blood test: can that optimize the treatment for prostate cancer? Listen to Professor Henrik Grönberg, who recently received the award “Cancer Researcher of the Year in 2022” by the Swedish Cancer Society. He tells us about the ProBio study which has the potential to revolutionize the treatment of prostate cancer. Guest: Professor Henrik Grönberg By: Annette Andrén and Gustav Widar Contact us: podcast@samnordic.se For more info, visit www.samnordic.se
– I tell my kids that I am probably not going to see them a lot but I am going to do stuff for a lot of patients out there who are living miserable lives. That is my motivation, to make somebody feel better. In this episode of Theragnostic Talks we get to meet Dr Laura Ravasi. She is Head of Global Medical Affairs at Telix Pharmaceuticals and travels all over Europe to find out more about the challenges and possibilities of tomorrow. Join us on the journey, from proof of concept to theragnostics of today. Guest: Dr Laura Ravasi By: Annette Andren and Gustav Widar Contact us: podcast@samnordic.se For more info, visit www.samnordic.se
When she found boxes of her father´s original work, Barbara Hertz decided to put all the puzzle pieces together. This episode of Theragnostic Talks is about Saul Hertz, the father of theragnostics. Saul Hertz was the first medical doctor to use radioactive iodine to treat hyperthyroidism, he pioneered the first targeted cancer therapies. Listen to his daughter Barbara telling us about his discoveries and insights, his eureka moment and about the fact that other people took credit for his work. Guest: Barbara Hertz By: Annette Andrén and Gustav Widar Contact us: podcast@samnordic.se For more info, visit www.samnordic.se
How can the most rare radioactive chemical element on earth be used in treatment for ovarian cancer? Listen to Postdoctoral Researcher Emma Aneheim talk about how their start-up company Alpha Therapy Solutions use Astatine-211 in combination with antibodies. What are the main benefits? And when will using Astatine-211 in cancer treatment be reality? Please join us in this week's exciting episode of Theragnostic Talks. Guest: Postdoctoral Researcher Emma Aneheim By: Anette Andren and Gustav Widar Contact us: podcast@samnordic.se For more info, visit www.samnordic.se
If you don´t have good evidence, the second best you can have is consensus from experts in the field. Meet Professor Silke Gillessen, one of the world´s leading experts in GU oncology and the lead organizer of APCCC, a conference where the world´s top prostate cancer experts get together. What are the main hot topics at the moment? And what difference does it really make for prostate cancer care, gathering this expertise? Please join us in this episode of Theragnostic Talks Guest: Prof. Silke Gillessen By: Annette Andrén and Gustav Widar Contact us: podcast@samnordic.se For more info, visit www.samnordic.se
It takes persistence to turn preclinical research into business. And it takes great teamwork to make it successful. In this episode of Theragnostic Talks we get to meet Dr Frances Johnson and Dr Michael Schultz. They founded Viewpoint Molecular Targeting, a radiopharmaceutical company with a theragnostic portfolio. Hear them talk about challenges along the way and why they believe in Alpha emitting isotopes. Enjoy! Guests: Dr Frances Johnson, Dr Michael Schultz By: Annette Andrén and Gustav Widar Contact us: podcast@samnordic.se For more info, visit www.samnordic.se
Professor Michael Hofman has contributed to some of the most important progress for imaging and treatment of prostate cancer. And his collaborative approach has brought together multi-disciplinary expertise from more than 10 centers around Australia. – If you have the energy to put together a clinical trial protocol I bet colleagues around your country will be happy to adopt it. It is a win-win for everyone. Please join us in this episode of Theragnostic Talks. Guest: Prof. Michael Hofman By: Annette Andrén and Gustav Widar Contact us: podcast@samnordic.se For more info, visit www.samnordic.se
By collaboration we can improve the scientific results and really make a difference. Don't miss this episode with the committed professor Stefano Fanti, devoted to his mission and always eager to spread the word about PET and prostate imaging. Ending up with breaking news about the EANM congress… Enjoy! Guest: Prof. Stefano Fanti By: Annette Andrén and Gustav Widar Contact us: podcast@samnordic.se For more info, visit www.samnordic.se
When Simone Leyden lost her 34 year old sister in a rare GI cancer she and her brother John decided to start a foundation. What struck them, when their sister was struggling, was that there was a huge difference in treatment and support for less common cancers, compared to more common ones. Please join us and listen to this episode of Theragnostic Talks Simone, founder and CEO of NeuroEndocrine Cancer. Guest: Simone Leyden, co-founder and CEO NeuroEndocrine Cancer By: Gustav Widar & Annette Andrén Contact us: podcast@samnordic.se For more info, visit www.samnordic.se
We gathered up with Oliver Sartor, Bernd Krause and Ken Hermann, co-authors of the VISION study, to talk about how it will impact the treatment of prostate cancer. The VISION study is the first international randomized open label phase III study that shows convincing results for a novel treatment of late-stage advanced prostate cancer. A targeted treatment for prostate cancer using radioactive 177Lu-PSMA-617. Successful? Without a doubt if you ask Oliver Sartor. – This is the theragnostic breakthrough we all have been waiting for. It's going to change the way we treat cancer. Join us on Theragnostic Talks! Guest: Oliver Sartor, Bernd Krause, Ken Hermann By: Gustav Widar Contact us: podcast@samnordic.se For more info, visit www.samnordic.se
What is immunoPET and radio immunotherapy? Meet Anna Wu, professor at City of Hope and research professor at UCLA, California. She explains why antibodies can be used instead of small molecules or peptides, how to use immunoPET for patient selection in immunotherapy and why a revolution of precision health is on its way. Guest: Anna Wu By: Gustav Widar and Annette Andrén Contact us: podcast@samnordic.se For more info, visit www.samnordic.se
In 5 to 10 years we are going to use theragnostics predominantly in combination with other therapies. Why? Because it gives us the opportunity to treat cancer in a totally different way. It's also a step forward to more personalized treatment. In this episode of Theragnostic Talks you get to meet Germo Gericke, Medical Officer at AAA. Enjoy! We apologize for bad sound quality in the beginning of this episode, but hold on – it gets better after 10 minutes. Guest: Germo Gericke By: Gustav Widar and Annette Andrén Contact us: podcast@samnordic.se For more info, visit www.samnordic.se
What professor Louise Emmett really loves is research. As a doctor, she says, you are able to change the lives for some people. With clinical research you can change the lives for millions of people. In this episode Louise Emmett explains theragnostics in prostate cancer and how prostate imaging can be used to understand the phenotype of the tumor. A step towards a more personalized treatment. Guest: Professor Louise Emmett By: Gustav Widar and Annette Andrén Contact us: podcast@samnordic.se For more info, visit www.samnordic.se
What are the challenges for theragnostic to be successful in the future? And how can we turn theragnostic innovations into successful and available therapies? In this episode of Theragnostic Talks we talk to Dr Oliver Sartor, the world-renowned prostate cancer expert and leader of Tulane's Prostate Cancer Research Program. Please join! Guest: Dr Oliver Sartor By: Gustav Widar and Annette Andrén Contact us: podcast@samnordic.se For more info, visit www.samnordic.se
“For nuclear medicine to be widely successful you have to care about people everywhere. We need to come up with solutions that make nuclear medicine really accessible for everyone. And the reason why we should do that is because it has a great cost beneficial profile”. The serial entrepreneur Dr Christian Behrenbruch is co-founder and CEO of Telix Pharmaceuticals and our guest in this episode of Theragnostic Talks. Enjoy! Guest: Dr Christian Behrenbruch By: Gustav Widar and Annette Andrén Contact us: podcast@samnordic.se For more info, visit www.samnordic.se
What does the future look like for more personalized therapy? And is sometimes no treatment the best option? In this episode we continue talking to professor Rodney Hicks, director of molecular imaging at the Peter MacCallum Cancer Centre and professor of medicine and radiology at the University of Melbourne. For Rodney Hicks, it's all about the patient. In a time when science focus on overall survival – he asks: what quality of life does it bring to the patient? Guest: Rodney Hicks By: Gustav Widar and Annette Andrén Contact us: podcast@samnordic.se For more info, visit www.samnordic.se
He is known as a pioneer, has over 500 peer-reviewed publications and has held numerous national and international research grants. Professor Rodney Hicks is our first guest on Theragnostic Talks, a podcast by SAM Nordic. He is director of molecular imaging at the Peter MacCallum Cancer Centre and professor of medicine and radiology at the University of Melbourne. In this episode Rodney Hicks talks about why imaging is important, why he attends at his patients funerals and why the treatment isn't science, but art. Guest: Rodney Hicks By: Gustav Widar and Annette Andrén Contact us: podcast@samnordic.se For more info, visit www.samnordic.se
How can theragnostic be a part of tomorrow's cancer care? How can industry, academia and healthcare cooperate in a successful way? And what is the next step, what is waiting around the corner? In our podcast Theragnostic Talks we will we talk to true experts from around the world. We will find out interesting science and get answers to our curious questions. Enjoy! By: Gustav Widar and Annette Andrén Contact us: podcast@samnordic.se For more info, visit www.samnordic.se
© 2020-2025 Ivy Podcast Discovery LLC
